David Zaccardelli, Verona Pharma CEO
May 9, 2024 01:23 PM EDT
Financing
Marketing

Verona inks fi­nanc­ing deal worth up to $650M ahead of COPD de­ci­sion

Nicole DeFeudis

Editor

Verona Phar­ma has se­cured up to $650 mil­lion to aid the po­ten­tial launch of its COPD can­di­date en­sifen­trine.

Un­der new

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Car­olyn Bertozzi’s lat­est biotech de­buts with $30M seed round and a sug­ary spin on im­munother­a­py

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times